Серцеві аритмії за невідкладних станів (гострий коронарний синдром, зокрема з реваскуляризацією): консенсусний документ Європейської асоціації серцевого ритму (EHRA), ухвалений Європейським товариством перкутанних серцево-судинних утручань (EAPCI) та Європейським товариством з питань гострих серцево-судинних станів (АССА)

Kalarus Z., Svendsen J.H., Capodanno D., Dan G.-A., De Maria E., Gorenek B., Jędrzejczyk-Patej Е., Mazurek M., Podolecki Т., Sticherling C., Tfelt-Hansen J., Traykov V., Lip G.Y.H.

Література 

1. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Europace 2015;17: 1601–87.
2. Solomon SD, Zelenkofske S, McMurray JJV, Finn PV, Velazquez E, Ertl G et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 2005;352:2581–8.
3. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877–83.
4. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004;351:2481–8.
5. Steinbeck G, Andresen D, Seidl K, Brachmann J, Hoffmann E, Wojciechowski D et al. Defibrillator implantation early after myocardial infarction. N Engl J Med 2009;361:1427–36.
6. Kosmidou I, Embacher M, McAndrew T, Dizon JM, Mehran R, Ben-Yehuda O et al. Early ventricular tachycardia or fibrillation in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention and impact on mortality and stent thrombosis (from the harmonizing outcomes with revascularization and stents in acute myocardial infarction trial). Am J Cardiol 2017;120:1755–60.
7. Piccini JP, White JA, Mehta RH, Lokhnygina Y, Al-Khatib SM, Tricoci P et al. Sustained ventricular tachycardia and ventricular fibrillation complicating nonST-segment-elevation acute coronary syndromes. Circulation 2012;126:41–9.
8. Demidova MM, Carlson J, Erlinge D, Platonov PG. Predictors of ventricular fibrillation at reperfusion in patients with acute ST-elevation myocardial infarction treated by primary percutaneous coronary intervention. Am J Cardiol 2015; 115:417–22.
9. Mehta RH, Starr AZ, Lopes RD, Hochman JS, Widimsky P, Pieper KS et al. Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention. JAMA 2009;301:1779–89.
10. Jabbari R, Risgaard B, Fosbøl EL, Scheike T, Philbert BT, Winkel BG et al. Factors associated with and outcomes after ventricular fibrillation before and during primary angioplasty in patients with st-segment elevation myocardial infarction. Am J Cardiol 2015;116:678–85.
11. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ et al. Heart disease and stroke statistics—2014 update. Circulation 2014;129:e28–292.
12. Luo J, Li H, Qin X, Liu B, Zhao J, Maihe G et al. Increased risk of ischemic stroke associated with new-onset atrial fibrillation complicating acute coronary syndrome: a systematic review and meta-analysis. Int J Cardiol 2018; 265:125–31.
13. Biasco L, Radovanovic D, Moccetti M, Rickli H, Roffi M, Eberli F et al. New-onset or pre-existing atrial fibrillation in acute coronary syndromes: two distinct phenomena with a similar prognosis. Rev Esp Cardiol 2019;72:383–91.
14. Zeymer U, Annemans L, Danchin N, Pocock S, Newsome S, Van de Werf et al. Impact of known or new-onset atrial fibrillation on 2-year cardiovascular event rate in patients with acute coronary syndromes: results from the prospective EPICOR Registry. Eur Hear Journal Acute Cardiovasc Care 2019;8:121–9.
15. Rene AG, Ge´ne´reux P, Ezekowitz M, Kirtane AJ, Xu K, Mehran R et al. Impact of atrial fibrillation in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention (from the HORIZONS-AMI [Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction] trial). Am J Cardiol 2014;113:236–42.
16. Podolecki T, Lenarczyk R, Kowalczyk J, Jedrzejczyk-Patej E, Swiatkowski A, Chodor P et al. Significance of atrial fibrillation complicating ST-segment elevation myocardial infarction. Am J Cardiol 2017;120:517–21.
17. Angeli F, Reboldi G, Garofoli M, Ramundo E, Poltronieri C, Mazzotta G et al. Atrial fibrillation and mortality in patients with acute myocardial infarction: a systematic overview and meta-analysis. Curr Cardiol Rep 2012;14:601–10.
18. Topaz G, Flint N, Steinvil A, Finkelstein A, Banai S, Keren G et al. Long term prognosis of atrial fibrillation in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention. Int J Cardiol 2017;240:228–33.
19. Podolecki T, Lenarczyk R, Kowalczyk J, Jedrzejczyk-Patej E, Chodor P, Mazurek M et al. Prognostic significance of complex ventricular arrhythmias complicating ST-segment elevation myocardial infarction. Am J Cardiol 2018;121:805–9.
20. Bigger JT, Dresdale FJ, Heissenbuttel RH, Weld FM, Wit AL. Ventricular arrhythmias in ischemic heart disease: mechanism, prevalence, significance, and management. Prog Cardiovasc Dis 1977;19:255–300.
21. Newby KH, Thompson T, Stebbins A, Topol EJ, Califf RM, Natale A. Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes. The GUSTO Investigators. Circulation 1998;98:2567–73.
22. Ruberman W, Weinblatt E, Goldberg JD, Frank CW, Chaudhary BS, Shapiro S. Ventricular premature complexes and sudden death after myocardial infarction. Circulation 1981;64:297–305.
23. Ruberman W, Weinblatt E, Goldberg JD, Frank CW, Shapiro S. Ventricular premature beats and mortality after myocardial infarction. N Engl J Med 1977;297: 750–7.
24. Farrell TG, Bashir Y, Cripps T, Malik M, Poloniecki J, Bennett ED et al. Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signalaveraged electrocardiogram. J Am Coll Cardiol 1991;18:687–97.
25. Mukharji J, Rude RE, Poole WK, Gustafson N, Thomas LJ, Strauss HW et al. Risk factors for sudden death after acute myocardial infarction: two-year follow-up. Am J Cardiol 1984;54:31–6.
26. Andresen D, Bethge K-P, Boissel J-P, VON Lettner E-R, Peyrieux J-C, SCHRo¨ DER R et al. Importance of quantitative analysis of ventricular arrhythmias for predicting the prognosis in low-risk postmyocardial infarction patients. European Infarction Study Group. Eur Heart J 1990;11:529–36.
27. Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med 1983;309:331–6.
28. Eldar M, Sievner Z, Goldbourt U, Reicher RH, Kaplinsky E, Behar S. Primary ventricular tachycardia in acute myocardial infarction: clinical characteristics and mortality. Ann Intern Med 1992;117:31–6.
29. Heidbuchel H, Tack J, Vanneste L, Ballet A, Ector H, Van de Werf F. Significance of arrhythmias during the first 24 hours of acute myocardial infarction treated with alteplase and effect of early administration of a beta-blocker or a bradycardiac agent on their incidence. Circulation 1994;89:1051–9.
30. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997;349:675–82.
31. Mont L, Cinca J, Blanch P, Blanco J, Figueras J, Brotons C et al. Predisposing factors and prognostic value of sustained monomorphic ventricular tachycardia in the early phase of acute myocardial infarction. J Am Coll Cardiol 1996;28:1670–6.
32. Al-Khatib SM, Granger CB, Huang Y, Lee KL, Califf RM, Simoons ML et al. Sustained ventricular arrhythmias among patients with acute coronary syndromes with no ST-segment elevation: incidence, predictors, and outcomes. Circulation 2002;106:309–12.
33. Brady W, Meldon S, DeBehnke D. Comparison of prehospital monomorphic and polymorphic ventricular tachycardia: prevalence, response to therapy, and outcome. Ann Emerg Med 1995;25:64–70.
34. Volpi A, Cavalli A, Santoro L, Negri E. Incidence and prognosis of early primary ventricular fibrillation in acute myocardial infarction–results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI-2) database. Am J Cardiol 1998;82:265–71.
35. Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF et al. Declining risk of sudden death in heart failure. N Engl J Med 2017;377:41–51.
36. Goraya TY, Jacobsen SJ, Kottke TE, Frye RL, Weston SA, Roger VL. Coronary heart disease death and sudden cardiac death: a 20-year population-based study. Am J Epidemiol 2003;157:763–70.
37. Stecker EC, Reinier K, Marijon E, Narayanan K, Teodorescu C, Uy-Evanado A et al. Public health burden of sudden cardiac death in the United States. Circ Arrhythm Electrophysiol 2014;7:212–7.
38. Niemeijer MN, van den Berg ME, Leening MJG, Hofman A, Franco OH, Deckers JW et al. Declining incidence of sudden cardiac death from 1990-2010 in a general middle-aged and elderly population: the Rotterdam Study. Heart Rhythm 2015;12:123–9.
39. McCarthy JJ, Carr B, Sasson C, Bobrow BJ, Callaway CW, Neumar RW et al. Out-of-hospital cardiac arrest resuscitation systems of care: a scientific statement from the American Heart Association. Circulation 2018;137:e645–60.
40. Zeyons F, Jesel L, Morel O, Kremer H, Messas N, Hess S et al. Out-of-hospital cardiac arrest survivors sent for emergency angiography: a clinical score for predicting acute myocardial infarction. Eur Hear J Acute Cardiovasc Care 2017;6: 103–11.
41. Tagami T, Yasunaga H, Yokota H. Antiarrhythmic drugs for out-of-hospital cardiac arrest with refractory ventricular fibrillation. Crit Care 2017;21:59.
42. Thomas JL, Bosson N, Kaji AH, Ji Y, Sung G, Shavelle DM et al. Treatment and outcomes of ST segment elevation myocardial infarction and out-of-hospital cardiac arrest in a regionalized system of care based on presence or absence of initial shockable cardiac arrest rhythm. Am J Cardiol 2014;114:968–71.
43. Fothergill RT, Watson LR, Virdi GK, Moore FP, Whitbread M. Survival of resuscitated cardiac arrest patients with ST-elevation myocardial infarction (STEMI) conveyed directly to a Heart Attack Centre by ambulance clinicians. Resuscitation 2014;85:96–8.
44. Khera R, CarlLee S, Blevins A, Schweizer M, Girotra S. Early coronary angiography and survival after out-of-hospital cardiac arrest: a systematic review and meta-analysis. Open Hear 2018;5:e000809.
45. Yannopoulos D, Bartos JA, Aufderheide TP, Callaway CW, Deo R, Garcia S et al. The evolving role of the cardiac catheterization laboratory in the management of patients with out-of-hospital cardiac arrest: a scientific statement from the American Heart Association. Circulation 2019;139:e530–52.
46. Abrams HC, McNally B, Ong M, Moyer PH, Dyer KS. A composite model of survival from out-of-hospital cardiac arrest using the Cardiac Arrest Registry to Enhance Survival (CARES). Resuscitation 2013;84:1093–8.
47. Fisher MB, Messerli A, Whayne TF. Characteristics, management, and results of out-of-hospital cardiac arrest (OHCA) with or without ST-segment elevation myocardial infarction (STEMI). Angiology 2018;69:189–91.
48. Viereck S, Møller TP, Rothman JP, Folke F, Lippert FK. Recognition of out-ofhospital cardiac arrest during emergency calls—a systematic review of observational studies. Scand J Trauma Resusc Emerg Med 2017;25:9.
49. Kudenchuk PJ, Brown SP, Daya M, Rea T, Nichol G, Morrison LJ et al. Amiodarone, lidocaine, or placebo in out-of-hospital cardiac arrest. N Engl J Med 2016;374:1711–22.
50. Kvakkestad KM, Sandvik L, Andersen GØ, Sunde K, Halvorsen S. Long-term survival in patients with acute myocardial infarction and out-of-hospital cardiac arrest: a prospective cohort study. Resuscitation 2018;122:41–7.
51. Ostenfeld S, Lindholm MG, Kjaergaard J, Bro-Jeppesen J, Møller JE, Wanscher M et al. Prognostic implication of out-of-hospital cardiac arrest in patients with cardiogenic shock and acute myocardial infarction. Resuscitation 2015;87:57–62.
52. Karam N, Bataille S, Marijon E, Giovannetti O, Tafflet M, Savary D et al. Identifying patients at risk for prehospital sudden cardiac arrest at the early phase of myocardial infarction: the e-MUST study (Evaluation en Me´decine d’Urgence des Strate´gies The´rapeutiques des infarctus du myocarde). Circulation 2016;134:2074–83.
53. Donnino MW, Salciccioli JD, Dejam A, Giberson T, Giberson B, Cristia C et al. APACHE II scoring to predict outcome in post-cardiac arrest. Resuscitation 2013;84:651–6.
54. Adrie C, Cariou A, Mourvillier B, Laurent I, Dabbane H, Hantala F et al. Predicting survival with good neurological recovery at hospital admission after successful resuscitation of out-of-hospital cardiac arrest: the OHCA score. Eur Heart J 2006;27:2840–5.
55. Maupain C, Bougouin W, Lamhaut L, Deye N, Diehl J-L, Geri G et al. The CAHP (Cardiac Arrest Hospital Prognosis) score: a tool for risk stratification after out-of-hospital cardiac arrest. Eur Heart J 2016;37:3222–8.
56. Martinell L, Nielsen N, Herlitz J, Karlsson T, Horn J, Wise MP et al. Early predictors of poor outcome after out-of-hospital cardiac arrest. Crit Care 2017;21: 1–10.
57. Aschauer S, Dorffner G, Sterz F, Erdogmus A, Laggner A. A prediction tool for initial out-of-hospital cardiac arrest survivors. Resuscitation 2014;85:1225–31.
58. Huang CH, Tsai MS, Chien KL, Chang WT, Wang TD, Chen SC et al. Predicting the outcomes for out-of-hospital cardiac arrest patients using multiple biomarkers and suspension microarray assays. Sci Rep 2016;6:27187.
59. Potpara TS, Mihajlovic M, Stankovic S, Jozic T, Jozic I, Asanin MR et al. External validation of the simple NULL-PLEASE clinical score in predicting outcome of out-of-hospital cardiac arrest. Am J Med 2017;130:1464.e13–1464.e21.
60. Gorenek B, Blomstrom Lundqvist C, Brugada Terradellas J, Camm AJ, Hindricks G, Huber K et al. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. Europace 2014;16: 1655–73.
61. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39: 119–77.
62. Dagres N, Hindricks G. Sudden cardiac death in acute coronary syndromes. Card Electrophysiol Clin 2017;9:725–30.
63. Nolan JP, Soar J, Zideman DA, Biarent D, Bossaert LL, Deakin C et al. European Resuscitation Council guidelines for resuscitation 2010 section 1. Executive summary. Resuscitation 2010;81:1219–76.
64. Piccini JP, Hranitzky PM, Kilaru R, Rouleau JL, White HD, Aylward PE et al. Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry). Am J Cardiol 2008;102:1427–32.
65. Zafari AM, Zarter SK, Heggen V, Wilson P, Taylor RA, Reddy K et al. A program encouraging early defibrillation results in improved in-hospital resuscitation efficacy. J Am Coll Cardiol 2004;44:846–52.
66. Dumas F, Cariou A, Manzo-Silberman S, Grimaldi D, Vivien B, Rosencher J et al. Immediate percutaneous coronary intervention is associated with better survival after out-of-hospital cardiac arrest: insights from the PROCAT (Parisian Region Out of hospital Cardiac ArresT) registry. Circ Cardiovasc Interv 2010;3: 200–7.
67. Spaulding CM, Joly L-M, Rosenberg A, Monchi M, Weber SN, Dhainaut J-FA et al. Immediate coronary angiography in survivors of out-of-hospital cardiac arrest. N Engl J Med 1997;336:1629–33.
68. Bardy GH, Poole JE, Kudenchuk PJ, Dolack GL, Kelso D, Mitchell R. A prospective randomized repeat-crossover comparison of antitachycardia pacing with low-energy cardioversion. Circulation 1993;87:1889–96.
69. Roolvink V, Iba´~nez B, Ottervanger JP, Pizarro G, van Royen N, Mateos A et al. Early intravenous beta-blockers in patients with ST-segment elevation myocardial infarction before primary percutaneous coronary intervention. J Am Coll Cardiol 2016;67:2705–15.
70. Reddy YM, Chinitz L, Mansour M, Bunch TJ, Mahapatra S, Swarup V et al. Percutaneous left ventricular assist devices in ventricular tachycardia ablation: multicenter experience. Circ Arrhythm Electrophysiol 2014;7:244–50.
71. Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX et al. Early intravenous then oral metoprolol in 45, 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1622–32.
72. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med 2001;345:1473–82.
73. Hine LK, Laird N, Hewitt P, Chalmers TC. Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction. Arch Intern Med 1989; 149:2694–8.
74. Mehta RH, Harjai KJ, Grines L, Stone GW, Boura J, Cox D et al. Sustained ventricular tachycardia or fibrillation in the cardiac catheterization laboratory among patients receiving primary percutaneous coronary intervention: incidence, predictors, and outcomes. J Am Coll Cardiol 2004;43:1765–72.
75. Terkelsen CJ, Sørensen JT, Kaltoft AK, Nielsen SS, Thuesen L, Bøtker H-E et al. Prevalence and significance of accelerated idioventricular rhythm in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol 2009;104:1641–6.
76. Janse MJ, Wit AL. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev 1989;69:1049–169.
77. Said M, Becerra R, Valverde CA, Kaetzel MA, Dedman JR, Mundi~na Weilenmann C et al. Calcium-calmodulin dependent protein kinase II (CaMKII): a main signal responsible for early reperfusion arrhythmias. J Mol Cell Cardiol 2011;51:936–44.
78. Pogwizd SM, Corr PB. Electrophysiologic mechanisms underlying arrhythmias due to reperfusion of ischemic myocardium. Circulation 1987;76:404–26.
79. Jabbari RV. Ventricular fibrillation and sudden cardiac death during myocardial infarction. Dan Med J 2016;63.
80. Chatterjee S, Chaudhuri D, Vedanthan R, Fuster V, Ibanez B, Bangalore S et al. Early intravenous beta-blockers in patients with acute coronary syndrome – a meta-analysis of randomized trials. Int J Cardiol 2013;168:915–21.
81. Piccini JP, Schulte PJ, Pieper KS, Mehta RH, White HD, Van de Werf F et al. Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction. Crit Care Med 2011;39:78–83.
82. Wolfe CL, Nibley C, Bhandari A, Chatterjee K, Scheinman M. Polymorphous ventricular tachycardia associated with acute myocardial infarction. Circulation 1991;84:1543–51.
83. Apostolakis S, Oeff M, Tebbe U, Fabritz L, Breithardt G, Kirchhof P. Flecainide acetate for the treatment of atrial and ventricular arrhythmias. Expert Opin Pharmacother 2013;14:347–57.
84. Mehta RH, Yu J, Piccini JP, Tcheng JE, Farkouh ME, Reiffel J et al. Prognostic significance of postprocedural sustained ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention (from the HORIZONS-AMI Trial). Am J Cardiol 2012;109:805–12.
85. Orvin K, Eisen A, Goldenberg I, Gottlieb S, Kornowski R, Matetzky S et al. Outcome of contemporary acute coronary syndrome complicated by ventricular tachyarrhythmias. Europace 2016;18:219–26.
86. Yan G-X, Joshi A, Guo D, Hlaing T, Martin J, Xu X et al. Phase 2 reentry as a trigger to initiate ventricular fibrillation during early acute myocardial ischemia. Circulation 2004;110:1036–41.
87. Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2016;37: 267–315.
88. Demidova MM, Smith JG, Ho ijer C-J, Holmqvist F, Erlinge D, Platonov PG. Prognostic impact of early ventricular fibrillation in patients with ST-elevation myocardial infarction treated with primary PCI. Eur Hear Journal Acute Cardiovasc Care 2012;1:302–11.
89. Bougouin W, Marijon E, Puymirat E, Defaye P, Celermajer DS, Le Heuzey J-Y et al. Incidence of sudden cardiac death after ventricular fibrillation complicating acute myocardial infarction: a 5-year cause-of-death analysis of the FAST-MI 2005 registry. Eur Heart J 2014;35:116–22.
90. Dekker LRC, Bezzina CR, Henriques JPS, Tanck MW, Koch KT, Alings MW et al. Familial sudden death is an important risk factor for primary ventricular fibrillation: a case-control study in acute myocardial infarction patients. Circulation 2006;114:1140–5.
91. Kaikkonen KS, Kortelainen M-L, Linna E, Huikuri HV. Family history and the risk of sudden cardiac death as a manifestation of an acute coronary event. Circulation 2006;114:1462–7.
92. Liang JJ, Hodge DO, Mehta RA, Russo AM, Prasad A, Cha Y-M. Outcomes in patients with sustained ventricular tachyarrhythmias occurring within 48 h of acute myocardial infarction: when is ICD appropriate? Europace 2014;16: 1759–66.
93. Hatzinikolaou-Kotsakou E, Tziakas D, Hotidis A, Stakos D, Floros D, Mavridis A et al. Could sustained monomorphic ventricular tachycardia in the early phase of a prime acute myocardial infarction affect patient outcome? J Electrocardiol 2007;40:72–7.
94. Gupta S, Pressman GS, Figueredo VM. Incidence of, predictors for, and mortality associated with malignant ventricular arrhythmias in non-ST elevation myocardial infarction patients. Coron Artery Dis 2010;21:460–5.
95. Volpi A, Cavalli A, Franzosi MG, Maggioni A, Mauri F, Santoro E et al. One-year prognosis of primary ventricular fibrillation complicating acute myocardial infarction. The GISSI (Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto miocardico) investigators. Am J Cardiol 1989;63:1174–8.
96. Khairy P, Thibault B, Talajic M, Dubuc M, Roy D, Guerra PG et al. Prognostic significance of ventricular arrhythmias post-myocardial infarction. Can J Cardiol 2003;19:1393–404.
97. Volpi A, Cavalli A, Turato R, Barlera S, Santoro E, Negri E. Incidence and shortterm prognosis of late sustained ventricular tachycardia after myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI-3) Data Base. Am Heart J 2001;142:87–92.
98. Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019;40:87–165.
99. Bhar-Amato J, Davies W, Agarwal S. Ventricular arrhythmia after acute myocardial infarction: ‘the perfect storm.’ Arrhythm Electrophysiol Rev 2017;6:134.
100. Stevenson WG, Friedman PL, Sager PT, Saxon LA, Kocovic D, Harada T et al. Exploring postinfarction reentrant ventricular tachycardia with entrainment mapping. J Am Coll Cardiol 1997;29:1180–9.
101. Zhang J, Cooper DH, Desouza KA, Cuculich PS, Woodard PK, Smith TW et al. Electrophysiologic scar substrate in relation to VT: noninvasive high-resolution mapping and risk assessment with ECGI. Pacing Clin Electrophysiol 2016;39: 781–91.
102. Cherry EM, Fenton FH, Gilmour RF. Mechanisms of ventricular arrhythmias: a dynamical systems-based perspective. Am J Physiol Heart Circ Physiol 2012;302: H2451–63.
103. Tsuji Y, Heijman J, Nattel S, Dobrev D. Electrical storm: recent pathophysiological insights and therapeutic consequences. Basic Res Cardiol 2013;108:336.
104. Schmidt A, Azevedo CF, Cheng A, Gupta SN, Bluemke DA, Foo TK et al. Infarct tissue heterogeneity by magnetic resonance imaging identifies enhanced cardiac arrhythmia susceptibility in patients with left ventricular dysfunction. Circulation 2007;115:2006–14.
105. Zaman S, Narayan A, Thiagalingam A, Sivagangabalan G, Thomas S, Ross DL et al. Long-term arrhythmia-free survival in patients with severe left ventricular dysfunction and no inducible ventricular tachycardia after myocardial infarction. Circulation 2014;129:848–54.
106. Zaman S, Sivagangabalan G, Narayan A, Thiagalingam A, Ross DL, Kovoor P. Outcomes of early risk stratification and targeted implantable cardioverterdefibrillator implantation after ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Circulation 2009;120: 194–200.
107. Zaman S, Taylor AJ, Stiles M, Chow C, Kovoor P. Programmed ventricular stimulation to risk stratify for early cardioverter-defibrillator implantation to prevent tachyarrhythmias following acute myocardial infarction (PROTECTICD): trial protocol, background and significance. Hear Lung Circ 2016;25: 1055–62.
108. Gatzoulis KA, Arsenos P, Trachanas K, Dilaveris P, Antoniou C, Tsiachris D et al. Signal-averaged electrocardiography: past, present, and future. J Arrhythmia 2018;34:222–9.
109. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016;37:2129–200.
110. Peck KY, Lim YZ, Hopper I, Krum H. Medical therapy versus implantable cardioverter-defibrillator in preventing sudden cardiac death in patients with left ventricular systolic dysfunction and heart failure: a meta-analysis of >35,000 patients. Int J Cardiol 2014;173:197–203.
111. AlJaroudi WA, Refaat MM, Habib RH, Al-Shaar L, Singh M, Gutmann R et al. Effect of angiotensin-converting enzyme inhibitors and receptor blockers on appropriate implantable cardiac defibrillator shock in patients with severe systolic heart failure (from the GRADE Multicenter Study). Am J Cardiol 2015;115: 924–31.
112. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406–12.
113. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225–37.
114. Zelia's A, Ste˛pi'nska J, Andres J, Tra˛bka-Zawicki A, Sadowski J, Z_ mudka K. Ten-year experience of an invasive cardiology centre with out-of-hospital cardiac arrest patients admitted for urgent coronary angiography. Kardiol Pol 2014;72: 687–99.
115. Stevenson WG, Wilber DJ, Natale A, Jackman WM, Marchlinski FE, Talbert T et al. Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction: the multicenter thermocool ventricular tachycardia ablation trial. Circulation 2008;118: 2773–82.
116. Tanner H, Hindricks G, Volkmer M, Furniss S, Kuhlkamp V, Lacroix D et al. Catheter ablation of recurrent scar-related ventricular tachycardia using electroanatomical mapping and irrigated ablation technology: results of the prospective multicenter euro-VT-study. J Cardiovasc Electrophysiol 2010;21: 47–53.
117. Calkins H, Epstein A, Packer D, Arria AM, Hummel J, Gilligan DM et al. Catheter ablation of ventricular tachycardia in patients with structural heart disease using cooled radiofrequency energy: results of a prospective multicenter study. Cooled RF Multi Center Investigators Group. J Am Coll Cardiol 2000;35: 1905–14.
118. Chatterjee S, Udell JA, Sardar P, Lichstein E, Ryan JJ. Comparable benefit of b-blocker therapy in heart failure across regions of the world: meta-analysis of randomized clinical trials. Can J Cardiol 2014;30:898–903.
119. Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA 2006;295:165–71.
120. Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ et al. Randomised trial of effect of amiodarone on mortality in patients with leftventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997;349:667–74.
121. Kuck K-H, Schaumann A, Eckardt L, Willems S, Ventura R, Delacre´taz E et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet 2010;375:31–40.
122. Reddy VY, Reynolds MR, Neuzil P, Richardson AW, Taborsky M, Jongnarangsin K et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med 2007;357:2657–65.
123. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med 1991;324:781–8.
124. Stone GW, Kandzari DE, Mehran R, Colombo A, Schwartz RS, Bailey S et al. Percutaneous recanalization of chronically occluded coronary arteries. Circulation 2005;112:2364–72.
125. van der Schaaf RJ, Vis MM, Sjauw KD, Koch KT, Baan J, Tijssen JGP et al. Impact of multivessel coronary disease on long-term mortality in patients with STelevation myocardial infarction is due to the presence of a chronic total occlusion. Am J Cardiol 2006;98:1165–9.
126. Tajstra M, Gasior M, Gierlotka M, Pres D, Hawranek M, Trzeciak P et al. Comparison of five-year outcomes of patients with and without chronic total occlusion of noninfarct coronary artery after primary coronary intervention for ST-segment elevation acute myocardial infarction. Am J Cardiol 2012;109: 208–13.
127. Rasoul S, Ottervanger JP, de Boer M-J, Dambrink J-HE, Hoorntje JCA, Marcel Gosselink AT et al. Predictors of 30-day and 1-year mortality after primary percutaneous coronary intervention for ST-elevation myocardial infarction. Coron Artery Dis 2009;20:415–21.
128. Kelbæk H, Terkelsen CJ, Helqvist S, Lassen JF, Clemmensen P, Kløvgaard L et al. Randomized comparison of distal protection versus conventional treatment in primary percutaneous coronary intervention: the drug elution and distal protection in ST-elevation myocardial infarction (DEDICATION) trial. J Am Coll Cardiol 2008;51:899–905.
129. Claessen BE, Dangas GD, Weisz G, Witzenbichler B, Guagliumi G, Mockel M et al. Prognostic impact of a chronic total occlusion in a non-infarct-related artery in patients with ST-segment elevation myocardial infarction: 3-year results from the HORIZONS-AMI trial. Eur Heart J 2012;33:768–75.
130. Zhang H-P, Zhao Y, Li H, Tang G-D, Ai H, Zheng N-X et al. Impact of chronic total occlusion in a noninfarct-related artery on clinical outcomes in patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Medicine (Baltimore) 2016;95:e2441.
131. Nishikawa T, Fujino M, Nakajima I, Asaumi Y, Kataoka Y, Anzai T et al. Prognostic impact of chronic total coronary occlusion on long-term outcomes in implantable cardioverter-defibrillator recipients with ischaemic heart disease. Europace 2017;19:1153–62.
132. Hannan EL, Wu C, Walford G, Holmes DR, Jones RH, Sharma S et al. Incomplete revascularization in the era of drug-eluting stents: impact on adverse outcomes. JACC Cardiovasc Interv 2009;2:17–25.
133. Wu C, Dyer A-M, Walford G, Holmes DR, King SB, Stamato NJ et al. Incomplete revascularization is associated with greater risk of long-term mortality after stenting in the era of first generation drug-eluting stents. Am J Cardiol 2013;112:775–81.
134. Elhendy A, Chapman S, Porter TR, Windle J. Association of myocardial ischemia with mortality and implantable cardioverter-defibrillator therapy in patients with coronary artery disease at risk of arrhythmic death. J Am Coll Cardiol 2005; 46:1721–6.
135. Alderman EL, Bourassa MG, Cohen LS, Davis KB, Kaiser GG, Killip T et al. Tenyear follow-up of survival and myocardial infarction in the randomized Coronary Artery Surgery Study. Circulation 1990;82:1629–46.
136. Bell MR, Gersh BJ, Schaff HV, Holmes DR, Fisher LD, Alderman EL et al. Effect of completeness of revascularization on long-term outcome of patients with three-vessel disease undergoing coronary artery bypass surgery. A report from the Coronary Artery Surgery Study (CASS) Registry. Circulation 1992;86: 446–57.
137. Monde´sert B, Khairy P, Schram G, Shohoudi A, Talajic M, Andrade JG et al. Impact of revascularization in patients with sustained ventricular arrhythmias, prior myocardial infarction, and preserved left ventricular ejection fraction. Heart Rhythm 2016;13:1221–7.
138. Brockes C, Rahn-Scho¨ nbeck M, Duru F, Candinas R, Seifert B, Turina M. ICD implantation with and without combined myocardial revascularisation—incidence of ICD therapy and late survival. Thorac Cardiovasc Surg 2002;50:333–6.
139. Bourke JP, Richards DA, Ross DL, Wallace EM, McGuire MA, Uther JB. Routine programmed electrical stimulation in survivors of acute myocardial infarction for prediction of spontaneous ventricular tachyarrhythmias during follow-up: results, optimal stimulation protocol and cost-effective screening. J Am Coll Cardiol 1991;18:780–8.
140. Nageh MF, Kim JJ, Chen L, Yao JF. Implantable defibrillators for secondary prevention of sudden cardiac death in cardiac surgery patients with perioperative ventricular arrhythmias. J Am Heart Assoc 2014;3.
141. Stevenson WG, Khan H, Sager P, Saxon LA, Middlekauff HR, Natterson PD et al. Identification of reentry circuit sites during catheter mapping and radiofrequency ablation of ventricular tachycardia late after myocardial infarction. Circulation 1993;88:1647–70.
142. Kumar S, Sivagangabalan G, Thiagalingam A, West EB, Narayan A, Sadick N et al. Effect of reperfusion time on inducible ventricular tachycardia early and spontaneous ventricular arrhythmias late after ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Heart Rhythm 2011;8:493–9.
143. Ezekowitz JA, Rowe BH, Dryden DM, Hooton N, Vandermeer B, Spooner C et al. Systematic review: implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction. Ann Intern Med 2007;147:251–62.
144. Adabag AS, Therneau TM, Gersh BJ, Weston SA, Roger VL. Sudden death after myocardial infarction. JAMA 2008;300:2022–9.
145. Wilber DJ, Zareba W, Hall WJ, Brown MW, Lin AC, Andrews ML et al. Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation 2004;109:1082–4.
146. Goldenberg I, Moss AJ, McNitt S, Zareba W, Hall WJ, Andrews ML et al. Time dependence of defibrillator benefit after coronary revascularization in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 2006;47:1811–7.
147. Sredniawa B, Mazurek M, Lenarczyk R, Kowalski O, Kowalczyk J, Kalarus Z. Early therapy following myocardial infarction: arguments for and against implantable cardioverter-defibrillators. Future Cardiol 2010;6:315–23.
148. Elayi CS, Charnigo RJ, Heron PM, Lee BK, Olgin JE. Primary prevention of sudden cardiac death early post-myocardial infarction: root cause analysis for implantable cardioverter-defibrillator failure and currently available options. Circ Arrhythm Electrophysiol 2017;10:e005194.
149. Olgin JE, Pletcher MJ, Vittinghoff E, Wranicz J, Malik R, Morin DP et al. Wearable cardioverter–defibrillator after myocardial infarction. N Engl J Med 2018;379:1205–15.
150. Vest Prevention of Early Sudden Death Trial and VEST Registry (VEST). Clinical Trials.gov. https://clinicaltrials.gov/ct2/show/NCT01446965.
151. Solomon SD, Glynn RJ, Greaves S, Ajani U, Rouleau JL, Menapace F et al. Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study. Ann Intern Med 2001;134:451–8.
152. Mazurek M, Kowalczyk J, Lenarczyk R, Swiatkowski A, Kowalski O, Sedkowska A et al. The impact of unsuccessful percutaneous coronary intervention on shortand long-term prognosis in STEMI and NSTEMI. Catheter Cardiovasc Interv 2011;78:514–22.
153. Abbott JD, Ahmed HN, Vlachos HA, Selzer F, Williams DO. Comparison of outcome in patients with ST-elevation versus non-ST-elevation acute myocardial infarction treated with percutaneous coronary intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol 2007; 100:190–5.
154. Cox DA, Stone GW, Grines CL, Stuckey T, Zimetbaum PJ, Tcheng JE et al. Comparative early and late outcomes after primary percutaneous coronary intervention in ST-segment elevation and non-ST-segment elevation acute myocardial infarction (from the CADILLAC trial). Am J Cardiol 2006;98:331–7.
155. Terkelsen CJ, Lassen JF, Nørgaard BL, Gerdes JC, Jensen T, Gøtzsche LB-H et al. Mortality rates in patients with ST-elevation vs. non-ST-elevation acute myocardial infarction: observations from an unselected cohort. Eur Heart J 2005;26:18–26.
156. Thiele H, Kappl MJ, Linke A, Erbs S, Boudriot E, Lembcke A et al. Influence of time-to-treatment, TIMI-flow grades, and ST-segment resolution on infarct size and infarct transmurality as assessed by delayed enhancement magnetic resonance imaging. Eur Heart J 2006;28:1433–9.
157. Kandzari DE, Tcheng JE, Gersh BJ, Cox DA, Stuckey T, Turco M et al. Relationship between infarct artery location, epicardial flow, and myocardial perfusion after primary percutaneous revascularization in acute myocardial infarction. Am Heart J 2006;151:1288–95.
158. Bello D, Fieno DS, Kim RJ, Pereles FS, Passman R, Song G et al. Infarct morphology identifies patients with substrate for sustained ventricular tachycardia. J Am Coll Cardiol 2005;45:1104–8.
159. Yan AT, Shayne AJ, Brown KA, Gupta SN, Chan CW, Luu TM et al. Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation 2006;114:32–9.
160. Gradel C, Jain D, Batsford WP, Wackers FJ, Zaret BL. Relationship of scar and ischemia to the results of programmed electrophysiological stimulation in patients with coronary artery disease. J Nucl Cardiol 1997;4:379–86.
161. Gouda S, Abdelwahab A, Salem M, Hamid MA. Scar characteristics for prediction of ventricular arrhythmia in ischemic cardiomyopathy. Pacing Clin Electrophysiol 2015;38:311–8.
162. Yoshiga Y, Mathew S, Wissner E, Tilz R, Fuernkranz A, Metzner A et al. Correlation between substrate location and ablation strategy in patients with ventricular tachycardia late after myocardial infarction. Heart Rhythm 2012;9: 1192–9.
163. Woie L, Eftestøl T, Engan K, Kvaløy JT, Nilsen D, Ørn S. The heart rate of ventricular tachycardia following an old myocardial infarction is inversely related to the size of scarring. Europace 2011;13:864–8.
164. Sosa E, Scanavacca M, d’Avila A, Oliveira F, Ramires JA. Nonsurgical transthoracic epicardial catheter ablation to treat recurrent ventricular tachycardia occurring late after myocardial infarction. J Am Coll Cardiol 2000;35:1442–9.
165. Marchlinski FE, Callans DJ, Gottlieb CD, Zado E. Linear ablation lesions for control of unmappable ventricular tachycardia in patients with ischemic and nonischemic cardiomyopathy. Circulation 2000;101:1288–96.
166. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016;18:1609–78.
167. Lip G, Freedman B, De Caterina R, Potpara TS. Stroke prevention in atrial fibrillation: past, present and future. Comparing the guidelines and practical decision-making. Thromb Haemost 2017;117:1230–9.
168. Lip G, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B et al. Antithrombotic therapy for atrial fibrillation. CHEST Guideline and Expert Panel Report. Chest 2018;154:1121–201.
169. Borre ED, Goode A, Raitz G, Shah B, Lowenstern A, Chatterjee R et al. Predicting thromboembolic and bleeding event risk in patients with nonvalvular atrial fibrillation: a systematic review. Thromb Haemost 2018;118: 2171–87.
170. Mamas MA, Caldwell JC, Chacko S, Garratt CJ, Fath-Ordoubadi F, Neyses L. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail 2009;11:676–83.
171. Gupta S, Figueredo VM. Tachycardia mediated cardiomyopathy: pathophysiology, mechanisms, clinical features and management. Int J Cardiol 2014;172: 40–6.
172. Jabre P, Jouven X, Adnet F, Thabut G, Bielinski SJ, Weston SA et al. Atrial fibrillation and death after myocardial infarction. Circulation 2011;123: 2094–100.
173. Valgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J 2018;39:213–60.
174. Guenancia C, Toucas C, Fauchier L, Stamboul K, Garnier F, Mouhat B et al. High rate of recurrence at long-term follow-up after new-onset atrial fibrillation during acute myocardial infarction. Europace 2018;20:e179–88.
175. Lip GYH, Collet JP, Haude M, Byrne R, Chung EH, Fauchier L, Halvorsen S, Lau D, Lopez-Cabanillas N, Lettino M, Marin F, Obel I, Rubboli A, Storey RF, Valgimigli M H, 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace 2019;21:192–3.
176. Boriani G, Fauchier L, Aguinaga L, Beattie JM, Blomstrom Lundqvist C, Cohen A et al. European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS). Europace 2019;21:7–8.
177. Munger TM, Packer DL, Hammill SC, Feldman BJ, Bailey KR, Ballard DJ et al. A population study of the natural history of Wolff-Parkinson-White syndrome in Olmsted County, Minnesota, 1953-1989. Circulation 1993;87:866–73.
178. Roth A, Elkayam I, Shapira I, Sander J, Malov N, Kehati M et al. Effectiveness of prehospital synchronous direct-current cardioversion for supraventricular tachyarrhythmias causing unstable hemodynamic states. Am J Cardiol 2003;91: 489–91.
179. Neumar RW, Otto CW, Link MS, Kronick SL, Shuster M, Callaway CW et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010;122:S729–67.
180. Glatter KA, Dorostkar PC, Yang Y, Lee RJ, Van Hare GF, Keung E et al. Electrophysiological effects of ibutilide in patients with accessory pathways. Circulation 2001;104:1933–9.
181. Sellers TD, Campbell RW, Bashore TM, Gallagher JJ. Effects of procainamide and quinidine sulfate in the Wolff-Parkinson-White syndrome. Circulation 1977; 55:15–22.
182. Boahene KA, Klein GJ, Yee R, Sharma AD, Fujimura O. Termination of acute atrial fibrillation in the Wolff-Parkinson-White syndrome by procainamide and propafenone: importance of atrial fibrillatory cycle length. J Am Coll Cardiol 1990;16:1408–14.
183. Sclarovsky S, Kracoff OH, Strasberg B, Lewin RF, Agmon J. Paroxysmal atrial flutter and fibrillation associated with preexcitation syndrome: treatment with ajmaline. Am J Cardiol 1981;48:929–33.
184. Boriani G, Biffi M, Frabetti L, Azzolini U, Sabbatani P, Bronzetti G et al. Ventricular fibrillation after intravenous amiodarone in Wolff-Parkinson-White syndrome with atrial fibrillation. Am Heart J 1996;131:1214–6.
185. Morady F, Dicarlo LA, Baerman JM, Buitleir M. Effect of propranolol on ventricular rate during atrial fibrillation in the Wolff-Parkinson-White syndrome. Pacing Clin Electro 1987;10:492–6.
186. Garratt C, Antoniou A, Ward D, Camm AJ. Misuse of verapamil in pre-excited atrial fibrillation. Lancet 1989;1:367–9.
187. Wellens HJ, Durrer D. Effect of digitalis on atrioventricular conduction and circus-movement tachycardias in patients with Wolff-Parkinson-White syndrome. Circulation 1973;47:1229–33.
188. DiMarco JP, Miles W, Akhtar M. Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The Adenosine for PSVT Study Group. Ann Intern Med 1990;113:104–10.
189. Huycke EC, Sung RJ, Dias VC, Milstein S, Hariman RJ, Platia EV. Intravenous diltiazem for termination of reentrant supraventricular tachycardia: a placebocontrolled, randomized, double-blind, multicenter study. J Am Coll Cardiol 1989; 13:538–44.
190. Hamer A, Peter T, Platt M, Mandel WJ. Effects of verapamil on supraventricular tachycardia in patients with overt and concealed Wolff-Parkinson-White syndrome. Am Heart J 1981;101:600–12.